Overview

Crossover Comparison of MultiHance and Dotarem

Status:
Completed

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

Summary

This study aims at a comparison between MultiHance at a dose of 0.1 mmol/kg and 0.05 mmol/kg and Dotarem at a dose of 0.1 mmol/kg in brain tumor patients to show superiority of MultiHance.

Phase:

Phase 4

Details

Lead Sponsor:

Bracco Diagnostics, Inc

Treatments:

Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate